Page 922 - Read Online

Mantovani et al. Hepatoma Res 2020;6:78 I http://dx.doi.org/10.20517/2394-5079.2020.75 Page 19 of 22

type 2 diabetes mellitus. J Clin Diagn Res 2017;11:OC04-7.
68. Mandal A, Bhattarai B, Kafle P, et al. Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver
disease. Cureus 2018;10:e3626.
69. Motta BM, Grander C, Gögele M, et al. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational
study. J Transl Med 2019;17:408.
70. Sporea I, Mare R, Popescu A, et al. Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using
vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience. J Clin Med
2020;9:1032.
71. Lombardi R, Airaghi L, Targher G, et al. Liver fibrosis by FibroScan independently of established cardiovascular risk parameters
®
associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int 2020;40:347-54.
72. Hamid S, Subhan Butt A, Sharif F, et al. Nonalcoholic fatty liver diseases among recently diagnosed patients with diabetes mellitus and
risk factors. Euroasian J Hepatogastroenterol 2019;9:9-13.
73. Lee YJ, Wang CP, Hung WC, et al. Common and unique factors and the bidirectional relationship between chronic kidney disease and
nonalcoholic fatty liver in type 2 diabetes patients. Diabetes Metab Syndr Obes 2020;13:1203-14.
74. El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2
diabetes. Eur J Gastroenterol Hepatol 2019;31:859-64.
75. Mangla N, Ajmera VH, Caussy C, et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2
diabetes. Clin Gastroenterol Hepatol 2020;18:744-6.e1.
76. Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ
2018;362:k2734.
77. Wang CC, Tseng TC, Hsieh TC, et al. Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. Kaohsiung J
Med Sci 2012;28:151-60.
78. Chen K, Sng WK, Quah JH, et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One
2020;15:e0236977.
79. Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a
population-based study. Aliment Pharmacol Ther 2012;36:772-81.
80. Zelber-Sagi S, Salomone F, Mlynarsky L. The mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease:
Evidence and plausible mechanisms. Liver Int 2017;37:936-49.
81. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268-79.
82. Bazick J, Donithan M, Neuschwander-Tetri BA, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and
NAFLD: guidelines for referral in NAFLD. Diabetes Care 2015;38:1347-55.
83. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-
steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148-55.
84. Loomba R, Abraham M, Unalp A, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family
history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51.
85. Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty
liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
World J Hepatol 2015;7:2610-8.
86. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic
review and meta-analysis. J Hepatol 2019;71:793-801.
87. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its
complications. J Clin Endocrinol Metab 2013;98:483-95.
88. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol
2003;13:15-21.
89. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged
Japanese men. Diabetes Care 2007;30:2940-4.
90. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean
adults. Diabet Med 2008;25:476-81.
91. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of
type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-9.
92. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes
mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-83.
93. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for
type 2 diabetes. Diabetes Care 2012;35:717-22.
94. Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes
mellitus. J Gastroenterol Hepatol 2013;28:142-7.
95. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk
of incident diabetes in a Korean population. Am J Gastroenterol 2013;108:1861-8.
96. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically
diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013;44:115-20.